Net revenue grew 3.8% in 3Q24 and 5.9% in 9M24, with improved cash flow and lower net debt, despite margin pressure from high-cost drugs and non-recurring provisions. Strategic projects are expected to drive further improvements from 4Q24.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.